REG - GSK PLC - TESARO update on AnaptysBio Inc. litigation

GSKAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260427:nRSa9962Ba&default-theme=true

RNS Number : 9962B  GSK PLC  27 April 2026

Issued: 27 April 2026, London UK

 

TESARO, a GSK subsidiary, provides update on AnaptysBio, Inc. litigation

 

 

 

GSK plc (LSE/NYSE: GSK) subsidiary, TESARO, Inc., confirms that the Delaware
Chancery Court has granted the motion to dismiss filed by AnaptysBio, Inc.
against TESARO's claim for anticipatory breach. The court's ruling does not
address the merits of the principal contractual dispute between the parties
and has no impact on TESARO's remaining claim against AnaptysBio for
declaratory judgment. GSK and TESARO are firmly of the view that these
allegations are entirely without merit and remain focused on pursuing that
claim at trial.

 

TESARO initiated this litigation following allegations made by AnaptysBio that
TESARO has not fulfilled certain requirements of the license agreement entered
in March 2014 between the parties and that AnaptysBio intends to revoke
TESARO's licence for dostarlimab.

 

Jemperli, which is the brand name for dostarlimab, is currently approved in
over 35 countries for use in certain endometrial cancers, the most common
gynaecologic cancer in the United States. GSK and TESARO have reported
significant growth for Jemperli driven by label expansions in endometrial
cancer, including in the US and EU. A robust and ambitious clinical trial
programme to evaluate the potential use of dostarlimab in additional cancers,
including rectal, colon and head and neck, is ongoing.

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at www.gsk.com
(https://www.gsk.com) .

 

 GSK enquiries
 Media:               Tim Foley          +44 (0) 20 8047 5502  (London)
                      Madison Goring     +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)
                      Alison Hunt        +1 540 742 3391       (Washington DC)

 Investor Relations:  Constantin Fest    +44 (0) 7831 826525   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Steph Mountifield  +44 (0) 7796 707505   (London)
                      Sam Piper          +44 (0) 7824 525779   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 3126       (Philadelphia)

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described in
the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025.

 

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUNVRRNWUSUUR



            Copyright 2019 Regulatory News Service, all rights reserved